↓ Skip to main content

Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms

Overview of attention for article published in Cancer Discovery, February 2016
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (92nd percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

1 news outlet
8 tweeters
2 patents
1 Facebook page


301 Dimensions

Readers on

162 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
Published in
Cancer Discovery, February 2016
DOI 10.1158/2159-8290.cd-15-0913
Pubmed ID

Eli L. Diamond, Benjamin H. Durham, Julien Haroche, Zhan Yao, Jing Ma, Sameer A. Parikh, Zhaoming Wang, John Choi, Eunhee Kim, Fleur Cohen-Aubart, Stanley Chun-Wei Lee, Yijun Gao, Jean-Baptiste Micol, Patrick Campbell, Michael P. Walsh, Brooke Sylvester, Igor Dolgalev, Olga Aminova, Adriana Heguy, Paul Zappile, Joy Nakitandwe, Chezi Ganzel, James D. Dalton, David W. Ellison, Juvianee Estrada-Veras, Mario Lacouture, William A. Gahl, Philip J. Stephens, Vincent A. Miller, Jeffrey S. Ross, Siraj M. Ali, Samuel R. Briggs, Omotayo Fasan, Jared Block, Sebastien Héritier, Jean Donadieu, David B. Solit, David M. Hyman, José Baselga, Filip Janku, Barry S. Taylor, Christopher Y. Park, Zahir Amoura, Ahmet Dogan, Jean-Francois Emile, Neal Rosen, Tanja A. Gruber, Omar Abdel-Wahab


Histiocytic neoplasms are clonal, hematopoietic disorders characterized by an accumulation of abnormal, monocyte-derived dendritic cells or macrophages in Langerhans Cell (LCH) and non-Langerhans (non-LCH) histiocytoses, respectively. The discovery of BRAFV600E mutations in ~50% of these patients provided the first molecular therapeutic target in histiocytosis. However, recurrent driving mutations in the majority of BRAFV600E-wildtype, non-LCH patients are unknown, and recurrent cooperating mutations in non-MAP kinase pathways are undefined for the histiocytic neoplasms. Through combined whole exome and transcriptome sequencing, we identified recurrent kinase fusions involving BRAF, ALK, and NTRK1, as well as recurrent, activating MAP2K1 and ARAF mutations in BRAFV600E-wildtype, non-LCH patients. In addition to MAP kinase pathway lesions, recurrently altered genes involving diverse cellular pathways were identified. Treatment of MAP2K1- and ARAF-mutated, non-LCH patients using MEK and RAF inhibitors, respectively, resulted in clinical efficacy demonstrating the importance of detecting and targeting diverse kinase alterations in these disorders.

Twitter Demographics

The data shown below were collected from the profiles of 8 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 162 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 162 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 31 19%
Other 23 14%
Student > Master 15 9%
Professor 14 9%
Student > Doctoral Student 13 8%
Other 36 22%
Unknown 30 19%
Readers by discipline Count As %
Medicine and Dentistry 78 48%
Biochemistry, Genetics and Molecular Biology 18 11%
Agricultural and Biological Sciences 17 10%
Immunology and Microbiology 4 2%
Business, Management and Accounting 2 1%
Other 10 6%
Unknown 33 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 19. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 23 September 2022.
All research outputs
of 22,514,578 outputs
Outputs from Cancer Discovery
of 3,614 outputs
Outputs of similar age
of 379,998 outputs
Outputs of similar age from Cancer Discovery
of 77 outputs
Altmetric has tracked 22,514,578 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,614 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 19.2. This one has done well, scoring higher than 80% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 379,998 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 92% of its contemporaries.
We're also able to compare this research output to 77 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.